JP3051444B2 - Composition for preventing or treating autoimmune nephritis - Google Patents
Composition for preventing or treating autoimmune nephritisInfo
- Publication number
- JP3051444B2 JP3051444B2 JP2331861A JP33186190A JP3051444B2 JP 3051444 B2 JP3051444 B2 JP 3051444B2 JP 2331861 A JP2331861 A JP 2331861A JP 33186190 A JP33186190 A JP 33186190A JP 3051444 B2 JP3051444 B2 JP 3051444B2
- Authority
- JP
- Japan
- Prior art keywords
- milk
- composition
- preventing
- autoimmune nephritis
- nephritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明は自己免疫性腎炎の予防または治療のための経
口組成物に関する。The present invention relates to an oral composition for preventing or treating autoimmune nephritis.
［従来の技術］ 自己免疫性腎炎は免疫寛容の異常、すなわち、自己に
対する免疫作用が原因と考えられている。[Related Art] Autoimmune nephritis is considered to be caused by abnormal immune tolerance, that is, an immune action on self.
しかしながら、その予防薬あるいは治療薬や、それら
の効果が期待できる組成物はなく、もっぱら対症療法的
な治療薬として副腎皮質ステロイド剤、アスピリン、免
疫抑制剤等を投与しているにすぎない。However, there is no prophylactic or therapeutic agent or a composition that can be expected to exert their effects, and only corticosteroids, aspirin, immunosuppressants, and the like are administered solely as symptomatic therapeutic agents.
これら現在使用されている医薬品は何れも副作用があ
り、特に汎用されている副腎皮質ステロイド剤はその傾
向が強く、長期間の投与には細心の注意を要する。All of these currently used pharmaceuticals have side effects, and particularly widely used corticosteroids tend to have such a tendency, and careful administration is required for long-term administration.
［発明が解決しようとする課題］ いわゆる難病といわれる疫病の治療法等の調査研究に
ついては昭和47年以来厚生省公衆衛生局が特定疾患対策
室を設け、その実務担当としての特定疾患調査研究班が
鋭意研究した結果、患者本人の治療法のみならず、その
原因についても解明されつつある。[Problems to be Solved by the Invention] The Public Health Bureau of the Ministry of Health and Welfare has set up a specific disease countermeasure room since 1972 for research on the treatment of epidemics, which are so-called intractable diseases. As a result of intensive research, not only the treatment of the patient himself, but also the cause is being elucidated.
例えば、全身性エリテマトーデス、慢性関節リウマ
チ、全身性強皮症、リウマチ熱、シューグレン病等は患
者の免疫機構に何等かの異常が起こり、自己に対して免
疫作用が働いた結果、各疾患特有の症状が発現すること
が明らかになってきた。For example, systemic lupus erythematosus, rheumatoid arthritis, systemic scleroderma, rheumatic fever, Sjogren's disease, etc., have some abnormalities in the patient's immune system, and as a result of immunization against themselves, each disease is unique It has become clear that the symptoms appear.
また、これらの症状の中で微生物の感染により自己免
疫による炎症反応が悪化する例も知られている。In addition, among these symptoms, there is known an example in which an inflammatory reaction due to autoimmunity is worsened by infection with a microorganism.
しかしながら、免疫機構の異常がその発症の原因であ
ることが明らかになったものの、具体的に自己免疫性腎
炎を予防ならびに治療でき、しかも副作用のないものは
知られていない。However, although it has been found that abnormalities in the immune system are responsible for its onset, there is no known specific one that can prevent and treat autoimmune nephritis and has no side effects.
一方、哺乳類の乳児は母乳のみから生存および成長に
必要な栄養素の補給を受けていることは公知であり、こ
の中には免疫学上の諸要素も当然含まれている。On the other hand, it is known that mammalian infants receive nutrients necessary for survival and growth only from breast milk, and this naturally includes various immunological factors.
特に、乳中にイムノグロブリンは微生物感染の防止に
対して有効であることが明らかになっている。In particular, it has been found that immunoglobulin in milk is effective for preventing microbial infection.
本発明者らはこれらの点に着目し、鋭意努力の結果、
微生物性抗原で感作した牛より搾乳した乳を原料とした
組成物には自己免疫性腎炎に対して極めて有効な効果が
あることを見出した。The present inventors have focused on these points, and as a result of earnest effort,
It has been found that a composition based on milk milked from a cow sensitized with a microbial antigen has a very effective effect on autoimmune nephritis.
［課題を解決するための手段］ 本発明は、微生物性抗原で感作した雌乳牛から搾乳し
た、該抗原に対する抗体を含有する乳を有効成分として
なることを特徴とする自己免疫性腎炎の予防または治療
用組成物を提供するものである。[Means for Solving the Problems] The present invention is directed to the prevention of autoimmune nephritis, characterized in that milk containing an antibody against the antigen, expressed from a cow sensitized with a microbial antigen, is used as an active ingredient. Alternatively, it provides a therapeutic composition.
本発明において使用する抗原は微生物由来のものであ
れば病原性、非病原性いずれでもよい。The antigen used in the present invention may be pathogenic or non-pathogenic as long as it is derived from a microorganism.
その具体例としては、例えば、第１表に示す微生物や
リウマチ熱の原因菌であるＡ群β型溶連菌、さらに各種
のウイルスが挙げられる。Specific examples thereof include, for example, the microorganisms shown in Table 1, group A β-type streptococci that are the causative bacteria of rheumatic fever, and various viruses.
雌牛を感作するには、例えば、第１表に示す微生物群
（以下「Ｓ−100抗原」と称する）から選択した１種ま
たは２種以上の微生物性抗原を産乳期の雌牛に注射する
ことにより感作することができる。この際、さらに目的
の品質の乳を得るためには抗原を数回に分けて投与、感
作することが望ましい。To sensitize a cow, for example, one or more microbial antigens selected from the group of microorganisms shown in Table 1 (hereinafter referred to as "S-100 antigen") are injected into a lactating cow. It can be sensitized. At this time, in order to further obtain milk of a desired quality, it is desirable to administer and sensitize the antigen in several times.
このようにして得た乳には感作した抗原に対する抗
体、すなわち、特異的イムノグロブリンが含まれてい
る。The milk thus obtained contains antibodies to the sensitized antigen, ie, specific immunoglobulins.
以上の操作で得られた感作雌牛から搾乳した乳（以下
「高度免疫乳」と称する）を有効成分とした組成物は後
記実施例に示すごとく、自己免疫性腎炎の発症を抑制す
ることができ、自己免疫性腎炎予防、治療に有用であ
る。 As shown in Examples below, the composition containing milk expressed from the sensitized cow obtained by the above operation and milked from the sensitized cow (hereinafter referred to as “hyperimmune milk”) can suppress the onset of autoimmune nephritis. It is useful for preventing and treating autoimmune nephritis.
本発明の高度免疫乳を有効成分とした自己免疫性腎炎
の予防または治療用組成物としては乳のまま、あるいは
該高度免疫乳に含まれる抗体活性が損なわれないように
加工した粉乳、これらを用いて常法に従い製造される、
飲料、ヨーグルト、菓子類、例えば、粒状菓子等が挙げ
られる。As a composition for the prevention or treatment of autoimmune nephritis comprising the hyperimmune milk of the present invention as an active ingredient, milk powder as it is, or milk powder processed so that the antibody activity contained in the hyperimmune milk is not impaired, Manufactured according to a conventional method using
Beverages, yogurt, confectionery, for example, granular confectionery and the like.
これらは通常の乳および前記のような乳加工品と同様
にして摂食でき、通常の摂食において毒性は認められな
い。These can be ingested in the same manner as ordinary milk and processed milk products as described above, and no toxicity is observed in ordinary eating.
［実施例］ 以下に、実施例を示し、本発明を具体的に説明する。EXAMPLES Hereinafter, the present invention will be described specifically with reference to Examples.
実施例１ ［高度免疫乳の調整］ 特開昭57−188523号公報に開示された方法に準じて高
度免疫乳を得た。Example 1 [Preparation of hyperimmune milk] Hyperimmune milk was obtained according to the method disclosed in JP-A-57-188523.
産乳期の雌牛５頭に第１表に示した微生物性抗原（Ｓ
−100抗原）からなる多価ワクチンで免疫した。多価ワ
クチンの注射は週１回の間隔で４週間連続して注射し
た。Microbial antigens (S
-100 antigen). Multivalent vaccine injections were given at weekly intervals for four consecutive weeks.
以上の方法で免疫化した雌牛から搾乳した乳から抗体
が損なわれないように管理された条件下で脱脂粉乳を得
た。Skim milk powder was obtained from milk milked from cows immunized in the manner described above under controlled conditions so that antibodies were not impaired.
以下の実施例で供試した試料は次のとおりである。 The samples tested in the following examples are as follows.
高度免疫乳；上記方法で得た脱脂粉乳 対照乳 ；市販の脱脂粉乳 実施例２ ８週齢雌の自己免疫モデルマウス（（NZB×NZW）F1）
20匹を準備した。高度免疫乳または対照乳48.9gと混合
飼料51.1gとの割合で混合したものを各々10匹に自由摂
食させた。Highly immunized milk; skim milk powder obtained by the above method Control milk; commercially available skim milk powder Example 2 8-week-old female autoimmune model mouse ((NZB × NZW) F 1 )
20 were prepared. A mixture of hyperimmune milk or control milk at a ratio of 48.9 g and a mixed feed at a ratio of 51.1 g was fed freely to 10 animals each.
高度免疫乳群および対照群とも18、22、26、28、30、
32、34、38、40、42週齢に尿を回収して検査した。尿中
の蛋白が100mg/dl以上検出されたものを自己免疫病の発
症とした。18, 22, 26, 28, 30, both hyperimmune and control groups
Urine was collected and examined at 32, 34, 38, 40, and 42 weeks of age. An autoimmune disease was detected when protein in urine was detected at 100 mg / dl or more.
なお、蛋白尿の測定はエームス尿検査試験紙アルブス
ティクス（マイルス・三共）を用いた。The proteinuria was measured using Ames urine test strip Albustics (Miles Sankyo).
結果は第１図に示した。 The results are shown in FIG.
高度免疫乳群（●印）および対照乳群（○印）ともル
ープス腎炎を発症するが、高度免疫乳群はループス腎炎
の指標となる蛋白尿の検出される時期が遅れ、自己免疫
性腎炎の発症を防止している。Both the hyperimmune milk group (●) and the control milk group (○) develop lupus nephritis, but the hyperimmune milk group has delayed detection of proteinuria, an indicator of lupus nephritis, Prevents onset.
実施例３ 前記実施例２のマウスを継続して飼育した結果、高度
免疫乳群の50％生存率は66週齢であった。一方、対照乳
群の50％生存率は56週齢であった。Example 3 As a result of continuously breeding the mouse of Example 2, the 50% survival rate of the hyperimmune milk group was 66 weeks of age. On the other hand, the 50% survival rate of the control milk group was 56 weeks of age.
実施例４ 前記実施例２のマウスの血漿抗DNA抗体価をELISA法に
より測定した。Example 4 The plasma anti-DNA antibody titer of the mouse of Example 2 was measured by ELISA.
その結果、腎炎発症の原因のひとつである血漿抗DNA
抗体の出現は対照乳群では17週齢で認められたのに対し
て高度免疫乳群では29週齢まで、その出現は抑えられ高
度免疫乳は自己免疫性腎炎の発症を防止した。As a result, plasma anti-DNA, one of the causes of nephritis
The appearance of antibodies was observed at 17 weeks of age in the control milk group, but was suppressed until the age of 29 weeks in the hyperimmune milk group, and the hyperimmune milk prevented the onset of autoimmune nephritis.
［発明の効果］ 以上のとおり、本発明の微生物性抗原で感作した雌乳
牛から搾乳した乳を有効成分とする組成物は自己免疫性
腎炎の予防および治療に有効である。また、本発明の組
成物は食品として供給可能であり、毎日食することによ
り自己免疫性腎炎の予防および治療ができる。[Effects of the Invention] As described above, the composition containing milk expressed from cows sensitized with the microbial antigen of the present invention as an active ingredient is effective for prevention and treatment of autoimmune nephritis. In addition, the composition of the present invention can be supplied as food, and can be eaten every day to prevent and treat autoimmune nephritis.
さらに、本発明の組成物は感作した微生物に対する特
異的イムノグロブリンを含有することから、これを食す
ることにより、これらの微生物の感染を主因とする疾病
の防止、あるいはこれらの微生物の感染により引き起こ
される他の疾病の炎症の悪化に対する防止効果等が期待
できる。Further, since the composition of the present invention contains a specific immunoglobulin for sensitized microorganisms, by eating it, prevention of diseases mainly caused by infection of these microorganisms, or infection by these microorganisms, It can be expected to have an effect of preventing inflammation of other diseases to be caused.
第１図は自己免疫性腎炎の発症防止効果を示すグラフで
ある。FIG. 1 is a graph showing the effect of preventing the onset of autoimmune nephritis.
フロントページの続き (73)特許権者 999999999 兼松株式会社 東京都港区芝浦１丁目２番１号 (72)発明者 室崎 伸二 福岡県福岡市西区姪の浜１丁目24番27― 102号 (72)発明者 石田 篤識 福岡県福岡市博多区千代４丁目65番29― 406号 (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 39/395 A61P 13/12 A61P 29/00 A61P 37/00 ＢＩＯＴＥＣＨＡＢＳ（ＳＴＮ) ＣＡ（ＳＴＮ) ＭＥＤＬＩＮＥ（ＳＴＮ)Continued on the front page (73) Patent holder 999999999 Kanematsu Co., Ltd. 1-2-1, Shibaura, Minato-ku, Tokyo (72) Inventor Shinji Murosaki 24-27-102, Meinohama 1-2-27, Nishi-ku, Fukuoka, Fukuoka (72) Invention Person Atsushi Ishida 4-65-29-406, Chiyo 4-chome, Hakata-ku, Fukuoka City, Fukuoka (58) Field surveyed (Int.Cl. 7 , DB name) A61K 39/395 A61P 13/12 A61P 29/00 A61P 37 / 00 BIOTECHABS (STN) CA (STN) MEDLINE (STN)
Claims (3)
た、その抗体を含有する乳を有効成分としてなることを
特徴とする自己免疫性腎炎の予防または治療用組成物。1. A composition for preventing or treating autoimmune nephritis, characterized by comprising as an active ingredient milk containing an antibody expressed from a cow sensitized with a microbial antigen.
（１）記載の組成物。2. The composition according to claim 1, wherein the microbial antigen is derived from a pathogenic bacterium.
ばれた１種もしくは２種以上である請求項（１）記載の
組成物。 3. The composition according to claim 1, wherein the microbial antigen is one or more selected from the group of the following microorganisms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2331861A JP3051444B2 (en) | 1990-11-28 | 1990-11-28 | Composition for preventing or treating autoimmune nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2331861A JP3051444B2 (en) | 1990-11-28 | 1990-11-28 | Composition for preventing or treating autoimmune nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04198136A JPH04198136A (en) | 1992-07-17 |
| JP3051444B2 true JP3051444B2 (en) | 2000-06-12 |
Family
ID=18248470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2331861A Expired - Lifetime JP3051444B2 (en) | 1990-11-28 | 1990-11-28 | Composition for preventing or treating autoimmune nephritis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3051444B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753100B1 (en) * | 1996-09-10 | 1999-04-09 | Marchandise Jean | HOMEOPATHIC COMPOSITION COMPRISING A PLURALITY OF DILUTIONS |
| CN1059128C (en) * | 1997-08-28 | 2000-12-06 | 王文荣 | Milk powder containing specific immunity globulin and its prodn. method |
| GB9920481D0 (en) * | 1999-09-01 | 1999-11-03 | Oxoid Ltd | Improvements in or relating to diagnosis of neuralgic or neuritic conditions |
| JP5361132B2 (en) * | 2006-03-10 | 2013-12-04 | 国立大学法人信州大学 | An oral immunomodulator containing immunoglobulin G, a method for producing the same, and a food or drink comprising the oral immunomodulator |
| JP5439127B2 (en) * | 2009-11-13 | 2014-03-12 | 株式会社さいわいメディカル | Treatment for psoriasis or atopic dermatitis |
| CN103169966B (en) * | 2013-04-09 | 2015-04-01 | 中国人民解放军军事医学科学院基础医学研究所 | Medicinal composition for treating systemic lupus erythematosus |
-
1990
- 1990-11-28 JP JP2331861A patent/JP3051444B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04198136A (en) | 1992-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tsubokura et al. | Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni‐infected chickens | |
| CN1229139C (en) | Prophylactic immue milk preparation against otitis | |
| EP0706400A1 (en) | Therapeutic formulation and method | |
| WO1997020577A1 (en) | Improved therapeutic formulation and method | |
| JPH08231424A (en) | Passive immunization of mammal by using antibody of bird | |
| KR20000048855A (en) | Oral administration of chicken yolk antibodies to treat disease | |
| EP0046909B1 (en) | Pharmaceutical composition | |
| Dahlgren et al. | Expression of a dietary protein in E. coli renders it strongly antigenic to gut lymphoid tissue. | |
| US4971794A (en) | Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili | |
| Tollemar et al. | Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients | |
| CA1219806A (en) | Production of antibodies | |
| JP3051444B2 (en) | Composition for preventing or treating autoimmune nephritis | |
| JPH10309178A (en) | Antiallergic agent and fermented food containing bifidus bacterium as active component | |
| CA2054830A1 (en) | Method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis, and it's formulated medicines | |
| Bullen | Iron‐binding proteins and other factors in milk responsible for resistance to Escherichia coli | |
| Whitelaw et al. | Development of immunity | |
| EP0914831B1 (en) | Biological product for preventive or therapeutic oral administration against canine parvovirosis | |
| WO1999002188A1 (en) | Hen egg yolk antibodies to clostridium difficile antigens and use in therapy for pseudomembranous colitis | |
| US20070264264A1 (en) | Method and composition for conferring immunity in mammals | |
| JPH1180197A (en) | Preventive and therapeutic agent against helicobacter pylori and relating infections | |
| JP3051268B2 (en) | Immunostimulation / infection protective agent | |
| EP0839050A1 (en) | Method of enhancing cell mediated immune responses | |
| JP3150162B2 (en) | Oral opportunistic infection prevention / treatment composition | |
| JP3055039B2 (en) | Gastrointestinal lymphocyte and mitogen active activator | |
| JP2689511B2 (en) | Food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090331 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100331 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100331 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110331 Year of fee payment: 11 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110331 Year of fee payment: 11 |